Early trial results indicate Moderna’s updated vaccine booster protects against Omicron
Moderna’s early trial results show its redesigned COVID-19 booster appears to provide stronger protection against the Omicron variant than its current vaccine. The shot targets both the Omicron variant and the original coronavirus strain and leads to an eight-fold increase in antibody levels.
High-risk patients have difficulty getting antiviral pills; FDA provider resource on Paxlovid can help
Some high-risk COVID patients are finding it difficult to get antiviral pills to treat coronavirus infections. Providers looking to prescribe Paxlovid for treatment of mild to moderate COVID-19 should review the FDA’s provider information. The information provides clarity on patient eligibility for Paxlovid and includes a patient eligibility screening checklist for use by prescribers. It also includes guidance on managing drug to drug interactions with Paxlovid.
Some people exposed to COVID never test positive
Some people may test negative for COVID and be infected with the virus, especially if they are fully vaccinated. Possible reasons for the negative test result include a vaccinated person’s body reacting very quickly to the virus upon exposure and the viral load being too low to show up on a test.
Children previously infected with COVID not protected against Omicron
Visit the College’s recently updated COVID-19 resource page for information related to COVID that allergists may need. The College’s federal response page has updates on the federal level.